OncoMatch/Clinical Trials/NCT06034561
Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia
Is NCT06034561 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Bortezomib for acute lymphoblastic leukemia, in relapse.
Treatment: Bortezomib — This is a interventional phase II study aiming to examine the complete response rate of a bortezomib-based salvage regimen in adults with refractory or relapsed acute lymphoblastic leukemia (ALL), seeking to compare outcomes with the available literature and with our historical data on relapsed/refractory ALL.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: bortezomib (bortezomib)
Prior exposure to bortezomib
Cannot have received: anthracycline
Exception: lifetime exposure ≤400mg/m2
Patients with more than 400mg/m2 lifetime exposure of anthracycline
Lab requirements
Kidney function
Creatinine ≤2.5 mg/dl
Liver function
Total bilirubin ≤2x ULN; transaminases ≤5x ULN
Cardiac function
No heart failure NYHA Class III or IV
Total bilirubin>2x upper limit of normal (ULN); Transaminases>5x ULN; Creatinine>2,5 mg/dl; Heart failure New York Heart Association (NYHA) Class III or IV
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify